Nouvelles
Montréal, Québec – Le 2 mai 2024 – Morphocell Technologies est ravi d'annoncer la nomination de Didier Leconte comme membre indépendant de son conseil d'administration, avec effet immédiat.
Montréal, QC, le 22 avril 2024 – Morphocell Technologies est ravie d'annoncer la nomination de Patrick Bedford en tant que notre nouveau Vice-Président des Affaires réglementaires.
Laval, Québec, 4 avril 2024 - Morphocell Technologies est fière d'annoncer la clôture d'un cycle de financement de série A de 40 millions de dollars américains. Cette étape financière importante, menée par Genson Capital, marque un moment décisif pour Morphocell.
Montréal, QC, le 17 janvier 2024 – Morphocell Technologies est ravie d'annoncer la nomination de Dr. Calley Hirsch en tant que sa nouvelle Vice-Présidente du Développement Préclinique.
Montréal, QC, le 24 juillet 2023 – Morphocell Technologies est ravie d'annoncer la nomination de Dr. Panos Chrysanthopoulos en tant que son nouveau Directeur du Développement.
Morphocell will present its progress, platform and preclinical data at Biotech Showcase 2023, one of the most important investor conferences, in San Francisco, CA.
Morphocell Technologies announces the publication of an innovative, scalable method for generating high-quality liver cells from induced pluripotent stem cells.
The US Patent Office (USPTO) has granted Morphocell Technologies patent number US11096388 covering the use of its Encapsulated Liver Tissue as part of a Bioartificial Liver Device
Morphocell partners with CQDM and Takeda Pharmaceuticals to support the development of its ReLiver technology for the treatment of liver failure
Morphocell Technologies, CQDM and Takeda Pharmaceutical Company Limited, with support from the Stem Cell Network, came together to fund a $979,200 Quantum Leap project that will enable Morphocell to generate preclinical efficacy and safety data in large animals for ReLiver®ELT
Morphocell has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 & 14-18, 2021.
Morphocell Technologies’ quest to transform the treatment of liver disease took another major step forward today with the announcement of new Stem Cell Network (SCN) funding for the Paganelli lab at Le Centre hospitalier universitaire Sainte-Justine.
The Morphocell team is gearing up for a busy and exciting 2020, starting with our participation at two can’t-miss conferences.
Stem cell commercialization expert Dr. Jennifer Moody appointed Chief Operating Officer beginning October 7th, 2019.
Morphocell Technologies Inc. held a successful pre-pre-Clinical Trial Application (CTA) meeting with Health Canada in August 2019.
Dr. Margaret Bywater Ekegärd is stepping down as Chief Executive Officer and President. She will continue as a member of the Board of Directors and assume a new role as a special adviser to Morphocell’s operations.
Morphocell Technologies signs exclusive license for the commercialisation of innovative stem cell-derived Encapsulated Liver Tissue technology.